Beigene logo

BGNE - Beigene Share Price

$311.97 -2.0  -0.6%

Last Trade - 07/05/21

Large Cap
Market Cap £20.47bn
Enterprise Value £17.51bn
Revenue £221.1m
Position in Universe 458th / 6858
Unlock BGNE Revenue
Relative Strength (%)
1m -5.41%
Volume Change (%)
10d / 3m
Price vs... (%)
52w High -19.8%
50d MA
200d MA
Growth & Value
12m Forecast Rolling Industry Market
Valuation (ttm) Industry Market
Margin of Safety
Qualifying GuruScreens
Financial Summary
Year End 31st Dec 2015 2016 2017 2018 2019 2020 2021E 2022E CAGR / Avg
8.82 1.07 238.4 198.2 428.2 308.9 1,019 1,384 +103.7%
Balance Sheet
FINANCIAL BRIEF: : For the fiscal year ended 31 December 2020, BeigeneLtd revenues decreased 28% to $308.9M. Net loss beforeextraordinary items increased 58% to $1.6B. Revenuesreflect United States segment decrease of 86% to $18.2M,Other segment decrease from $72M to $0K. Higher net lossreflects Research and development - Balancing increase of41% to $1.2B (expense), General and administrative -Balancing increase of 54% to $509.7M (expense).
Health Trend(F-Score)
0 1 2 3 4 5 6 7 8 9
Bankruptcy Score(Z-Score)
Earnings Manipulation Risk(M-Score)
Other Ratios
Recent History
Latest interim period vs. prior period Industry Market
3yr Compound Annual Growth Rate Industry Market
Graphical History


BGNE Revenue Unlock BGNE Revenue

Net Income

BGNE Net Income Unlock BGNE Revenue

Normalised EPS

BGNE Normalised EPS Unlock BGNE Revenue

PE Ratio Range

BGNE PE Ratio Range Unlock BGNE Revenue

Dividend Yield Range

BGNE Dividend Yield Range Unlock BGNE Revenue
Analyst Forecasts
Price Target:
( below Price)
31st Dec 2021
31st Dec 2022
Est. Long Term Growth Rate: Net Profit
Net Profit
Consensus Estimate
1m Change
3m Change
Analyst Consensus
Strong Sell Sell Hold Buy Strong Buy
EPS 2020 /  2021
BGNE EPS Forecasts Unlock BGNE Revenue
Profile Summary

BeiGene, Ltd. is principally engaged in biopharmaceutical business. The Company is mainly engaged in the research and development, production and sales of innovative molecularly targeted and immuno-oncology drugs for the treatment of cancer. The Company's main products include Zanubrutinib (BGB-3111), Tislelizumab (BGB-A317) and Pamiparib (BGB-290).

Last Annual December 31st, 2020
Last Interim December 31st, 2020
Incorporated October 28, 2010
Public Since February 3, 2016
No. of Shareholders: 160
No. of Employees: 5,300
Sector Healthcare
Industry Biotechnology & Medical Research
Index Nasdaq Composite ,
Exchange NASDAQ Global Select Market (Dual Listing)
Shares in Issue 91,789,823
Free Float (0.0%)
Eligible for
BGNE Share Price Performance
Share Price
Bid - Ask
Low - High
Day's Change
Avg Volume
Open - Close
Range (12m)
Latest News for BGNE
Upcoming Events for BGNE
Wednesday 16th June, 2021
Beigene Ltd Annual Shareholders Meeting
Thursday 17th June, 2021 Estimate
BeiGene Ltd Annual Shareholders Meeting
Wednesday 4th August, 2021 Estimate
Q2 2021 Beigene Ltd Earnings Release
Wednesday 3rd November, 2021 Estimate
Q3 2021 Beigene Ltd Earnings Release
Frequently Asked Questions for Beigene
What is the Beigene share price?

As of 07/05/21, shares in Beigene are trading at $311.97, giving the company a market capitalisation of £20.47bn. This share price information is delayed by 15 minutes.

How has the Beigene share price performed this year?

Shares in Beigene are currently trading at $311.97 and the price has moved by 0.103k% over the past 365 days. In terms of relative price strength - which takes into account the overall market trend - the Beigene price has moved by 41.79% over the past year.

What are the analyst and broker recommendations for Beigene?

Of the analysts with advisory recommendations for Beigene, there are there are currently 2 "buy" , 1 "hold" and 0 "sell" recommendations. The overall consensus recommendation for Beigene is Hold. You can view the full broker recommendation list by unlocking its StockReport.

When will Beigene next release its financial results?

Beigene is scheduled to issue upcoming financial results on the following dates:

Interim results are scheduled for: 2021-12-31
What is the Beigene dividend yield?

Beigene does not currently pay a dividend.

Does Beigene pay a dividend?

Beigene does not currently pay a dividend.

When does Beigene next pay dividends?

Beigene does not currently pay a dividend.

How do I buy Beigene shares?

To buy shares in Beigene you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.

What is the market cap of Beigene?

Shares in Beigene are currently trading at $311.97, giving the company a market capitalisation of £20.47bn.

Where are Beigene shares listed? Where are Beigene shares listed?

Here are the trading details for Beigene:

Country of listing: United States
Exchange: NSQ
Ticker Symbol: BGNE
What kind of share is Beigene?

Based on an overall assessment of its quality, value and momentum, Beigene is currently classified as a Sucker Stock. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.

Is there a Beigene share price forecast 2021?

Shares in Beigene are currently priced at $311.97. At that level they are trading at 16.4% discount to the analyst consensus target price of 0.00.

Analysts covering Beigene currently have a consensus Earnings Per Share (EPS) forecast of -13.3024248851 for the next financial year.

How can I tell whether the Beigene share price will go up?

An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Beigene. Over the past six months, the relative strength of its shares against the market has been -10.16%. At the current price of $311.97, shares in Beigene are trading at 7.88% against their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.

What is the Beigene PE Ratio?

We were not able to find PE ratio data for Beigene.

Who are the key directors of Beigene?

Beigene's management team is headed by:

John Oyler - CHM
Howard Liang - CFO
Michael Goller - NID
Donald Glazer - NID
Ranjeev Krishana - NID
Xiaodong Wang - CFD
Timothy Chen - NID
Xiaobin Wu - PRE
Jane Huang - OTH
Hing Ling Chau - SEC
Anthony Hooper - NED
Who are the major shareholders of Beigene?

Here are the top five shareholders of Beigene based on the size of their shareholding:

Amgen Inc Corporation
Percentage owned: 20.46% (18.8m shares)
Baker Bros. Advisors LP Hedge Fund
Percentage owned: 12.71% (11.7m shares)
Hillhouse Capital Advisors, Ltd. Investment Advisor/Hedge Fund
Percentage owned: 5.96% (5.47m shares)
Capital International Investors Investment Advisor
Percentage owned: 5.85% (5.37m shares)
Fidelity Management & Research Company LLC Investment Advisor
Percentage owned: 5.11% (4.69m shares)
Similar to BGNE
© Stockopedia 2021, Refinitiv, Share Data Services.
This site cannot substitute for professional investment advice or independent factual verification. To use it, you must accept our Terms of Use, Privacy and Disclaimer policies.